Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-GSK3 Rx and Earns $3 Million Milestone Payment From GSK



  Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-GSK3 Rx and Earns $3
                      Million Milestone Payment From GSK

PR Newswire

CARLSBAD, Calif., Nov. 26, 2013

CARLSBAD, Calif., Nov. 26, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
(NASDAQ: ISIS) announced today that it has initiated a Phase 1 study for
ISIS-GSK3[Rx] and earned a $3 million milestone payment from GlaxoSmithKline
(GSK).  ISIS-GSK3[Rx  ]is designed to inhibit the production of an undisclosed
target to treat a common viral infection.  Isis will develop ISIS-GSK3[Rx] to
Phase 2 proof-of-concept, after which GSK has an exclusive option to
in-license the program and further develop and commercialize the asset. 

(Logo:  http://photos.prnewswire.com/prnh/20130807/LA60006LOGO)  

"We are very pleased to advance ISIS-GSK3[Rx] into a clinical study in a
therapeutic area where there is a significant need for better therapies" said
B. Lynne Parshall, chief operating officer of Isis.  "The versatility and
broad applicability of our technology enables us to discover and develop
antisense drugs to a diverse range of targets.  We look forward to evaluating
this important new drug in this underserved disease space."

As a part of its alliance with GSK, Isis is eligible to earn additional
pre-licensing milestone payments from GSK as ISIS-GSK3[Rx] advances.  Isis is
also eligible to receive double-digit royalties on sales of ISIS-GSK3[Rx]. 
The alliance applies Isis' antisense drug discovery platform to discover and
develop new therapeutics against targets for rare and serious diseases,
including infectious diseases and some conditions causing blindness.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover
and develop novel drugs for its product pipeline and for its partners.  Isis'
broad pipeline consists of 31 drugs to treat a wide variety of diseases with
an emphasis on cardiovascular, metabolic, severe and rare diseases, including
neurological disorders, and cancer.  Isis' partner, Genzyme, is
commercializing Isis' lead product, KYNAMRO™, in the United States for the
treatment of patients with HoFH.  Isis' patents provide strong and extensive
protection for its drugs and technology.  Additional information about Isis is
available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis'
collaboration with GlaxoSmithKline, the discovery, development and potential
of drugs for rare and infectious diseases, and the development, activity,
therapeutic potential and safety of ISIS-GSK3[Rx].  Any statement describing
Isis' goals, expectations, financial or other projections, intentions or
beliefs is a forward-looking statement and should be considered an at-risk
statement.  Such statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around such drugs. 
Isis' forward-looking statements also involve assumptions that, if they never
materialize or prove correct, could cause its results to differ materially
from those expressed or implied by such forward-looking statements.  Although
Isis' forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors currently
known by Isis.  As a result, you are cautioned not to rely on these
forward-looking statements.  These and other risks concerning Isis' programs
are described in additional detail in Isis' annual report on Form 10-K for the
year ended December 31, 2012, and its most recent quarterly report on Form
10-Q, which are on file with the SEC. Copies of these and other documents are
available from the Company.

In this press release, unless the context requires otherwise, "Isis,"
"Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its
subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. 
Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is
a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals, Inc.

Website: http://www.isispharm.com
Contact: Isis Pharmaceuticals, D. Wade Walke, Ph.D., Vice President, Corporate
Communications and Investor Relations, +1-760-603-2741, or Amy Blackley,
Ph.D., Associate Director, Corporate Communications, +1-760-603-2772
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement